Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer.

OBJECTIVES To evaluate the ability of new computed tomography (CT) response criteria for solid tumors such as urothelial cancer (VTV; viable tumor volume) to predict overall survival (OS) in patients with metastatic bladder cancer treated with cabozantinib. MATERIALS AND METHODS We compared the relative capabilities of VTV, RECIST, MASS (morphology, attenuation, size, and structure), and Choi criteria, as well as volume measurements, to predict OS using serial follow-up contrast-enhanced CT exams in patients with metastatic urothelial carcinoma. Kaplan-Meier curves and 2-tailed log-rank tests compared OS based on early RECIST 1.1 response against each of the other criteria. A Cox proportional hazards model assessed response at follow-up exams as a time-varying covariate for OS. RESULTS We assessed 141 lesions in 55CT scans from 17 patients with urothelial metastasis, comparing VTV, RECIST, MASS, and Choi criteria, and volumetric measurements, for response assessment. Median follow-up was 4.5 months, range was 2-14 months. Only the VTV criteria demonstrated a statistical association with OS (p=0.019; median OS 9.7 vs. 3.5 months). CONCLUSION This pilot study suggests that VTV is a promising tool for assessing tumor response and predicting OS, using criteria that incorporate tumor volume and density in patients receiving antiangiogenic therapy for urothelial cancer. Larger studies are warranted to further validate these findings.

[1]  Vahid Yaghmai,et al.  Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[2]  D J Hawkes,et al.  Algorithms for radiological image registration and their clinical application , 1998, Journal of anatomy.

[3]  Max A. Viergever,et al.  A survey of medical image registration , 1998, Medical Image Anal..

[4]  Shetal N Shah,et al.  Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. , 2010, AJR. American journal of roentgenology.

[5]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[6]  J E Husband,et al.  Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society , 2004, British Journal of Cancer.

[7]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[8]  S. Steinberg,et al.  A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma. , 2013 .

[9]  P. Casali,et al.  Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma , 2009, Clinical Cancer Research.

[10]  Shetal N Shah,et al.  Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. , 2010, AJR. American journal of roentgenology.

[11]  Luis Ibanez,et al.  An open-source toolkit for the volumetric measurement of CT lung lesions. , 2010, Optics express.

[12]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Bellomi,et al.  Evaluation of the response to therapy of neoplastic lesions. , 2004, La Radiologia medica.

[14]  Jeffrey M. Solomon,et al.  New Image Analysis Technique for Quantitative Longitudinal Assessment of Lung Pathology on CT in Infected Rhesus Macaques , 2014, 2014 IEEE 27th International Symposium on Computer-Based Medical Systems.

[15]  H. Hatabu,et al.  Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. , 2012, AJR. American journal of roentgenology.

[16]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[17]  Vahid Yaghmai,et al.  Hepatic tumors: region-of-interest versus volumetric analysis for quantification of attenuation at CT. , 2012, Radiology.

[18]  V. Goh,et al.  Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. , 2011, Radiology.

[19]  Eric P Tamm,et al.  CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. , 2004, AJR. American journal of roentgenology.

[20]  V. Torri,et al.  High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment—Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria , 2010 .

[21]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[22]  Helen Hong,et al.  Automatic lung nodule matching on sequential CT images , 2008, Comput. Biol. Medicine.

[23]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[24]  D. Kwiatkowski,et al.  Targeting molecular aberrations in urothelial carcinoma: are we almost there? , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[25]  Vicky Goh,et al.  CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies , 2010, Cancer biology & therapy.